Results 211 to 220 of about 696,518 (307)

Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer. [PDF]

Front Immunol
Zhang B, Chen Z, Mao R, Zhu J, Cai W, Zhao B.   +5 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA. [PDF]

J Immunother Precis Oncol
europepmc   +1 more source

Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy. [PDF]

J Immunother Cancer
Fang J, Yu Y, Sun Y, Ji M, Jiang Y, Chen X, Yan C, Jin G.   +7 more
europepmc   +1 more source

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Blood Cancer Journal
Thomas Roberts, Grace Uwenedi, Rachel Bruton, Graham McIlroy, Sarah Damery, Panagiota Sylla, Nicola Logan, Sam Scott, May Lau, Ahmed Elzaidi, Siobhan Plass, Soumyajit Mallick, Katie Spencer, Christine Stephens, Christopher Bentley, Guy Pratt, Jianmin Zuo, Shankara Paneesha, Brian Willett, Paul Moss, Helen Parry   +20 more
doaj   +1 more source

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source

Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration. [PDF]

Chin Med J Pulm Crit Care Med
Wu X, Shi Y, Wang D, Liu B, Zhang Y, Zhang L, Qian F, Zhang W.   +7 more
europepmc   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1. [PDF]

Discov Oncol
El-Tanani M, Satyam SM, Rabbani SA, Rangraze IR, Matalka IIA, Muhana F, El-Tanani Y, Aljabali AAA, Khan MA, Parvez S, Porntaveetus T.   +10 more
europepmc   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source